Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Charly Courdy"'
Autor:
Charly Courdy, Loïc Platteeuw, Charlotte Ducau, Isabelle De Araujo, Emeline Boet, Ambrine Sahal, Estelle Saland, Valérie Edmond, Suzanne Tavitian, Sarah Bertoli, Pierre Cougoul, Fanny Granat, Laura Poillet, Caroline Marty, Isabelle Plo, Jean-Emmanuel Sarry, Stéphane Manenti, Véronique Mansat-De Mas, Carine Joffre
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are chronic malignancies associated with high-risk complications and suboptimal responses to JAK inhibitors such as ruxolitinib. A better understanding of cellular changes
Externí odkaz:
https://doaj.org/article/f1e0dd6471384291bb94a7aca671d64a
Autor:
Claudie Bosc, Nicolas Broin, Marjorie Fanjul, Estelle Saland, Thomas Farge, Charly Courdy, Aurélie Batut, Rawand Masoud, Clément Larrue, Sarah Skuli, Nicolas Espagnolle, Jean-Christophe Pagès, Alice Carrier, Frédéric Bost, Justine Bertrand-Michel, Jérôme Tamburini, Christian Récher, Sarah Bertoli, Véronique Mansat-De Mas, Stéphane Manenti, Jean-Emmanuel Sarry, Carine Joffre
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
How autophagy supports tumor cell metabolism is not fully clear. Here, the authors show that autophagy regulates lipid availability to support mitochondrial oxidative metabolism through mitochondria-endoplasmic reticulum contact sites, necessary for
Externí odkaz:
https://doaj.org/article/8cc02f2742d84833a052afbcc115d3a3
Publikováno v:
Biology, Vol 10, Iss 6, p 552 (2021)
Autophagy, which literally means “eat yourself”, is more than just a lysosomal degradation pathway. It is a well-known regulator of cellular metabolism and a mechanism implicated in tumor initiation/progression and therapeutic resistance in many
Externí odkaz:
https://doaj.org/article/802362d4442f43d5a8ba9742cda3f1d6
Autor:
Charly Courdy, Isabelle De Araujo, Ambrine Sahal, Charlotte Ducau, Estelle Saland, Valerie Edmond, Suzanne Tavitian, Sarah Bertoli, Pierre Cougoul, Laura Poillet, Isabelle Plo, Jean-Emmanuel Sarry, stephane manenti, Véronique De Mas, Carine Joffre
The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are chronic malignancies associated with high risk of complications and suboptimal responses to JAK inhibitors such as ruxolitinib. Therefore, better understanding cellular changes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f7a9d733aee301d6e76e7227437bcf6
https://doi.org/10.21203/rs.3.rs-1929377/v1
https://doi.org/10.21203/rs.3.rs-1929377/v1
